Gene: EGFR ×
Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.100 GeneticVariation BEFREE The effects of E7050 on HGF-induced resistance to reversible (gefitinib), irreversible (BIBW2992), and mutant-selective (WZ4002) EGFR-TKIs were determined using the EGFR mutant human lung cancer cell lines PC-9 and HCC827 with an exon 19 deletion and H1975 with an T790M secondary mutation. 22317763

2012
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.100 GeneticVariation BEFREE Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. 22899358

2012
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.100 GeneticVariation BEFREE Gefitinib analogue V1801 induces apoptosis of T790M EGFR-harboring lung cancer cells by up-regulation of the BH-3 only protein Noxa. 23185274

2012
dbSNP: rs1057519847
rs1057519847
EGFR
0.100 GeneticVariation BEFREE In preclinical studies, afatinib not only inhibited the growth of models with common activating EGFR mutations, but was also active in lung cancer models harboring wild-type EGFR or the EGFR L858R/T790M double mutant. 23664448

2013
dbSNP: rs1057519847
rs1057519847
EGFR
0.100 GeneticVariation BEFREE Gefitinib greatly enhanced NK cell cytotoxicity to lung cancer cells with EGFR L858R + T790M resistance mutation. 23937717

2013
dbSNP: rs1057519848
rs1057519848
EGFR
0.100 GeneticVariation BEFREE Gefitinib greatly enhanced NK cell cytotoxicity to lung cancer cells with EGFR L858R + T790M resistance mutation. 23937717

2013
dbSNP: rs1057519848
rs1057519848
EGFR
0.100 GeneticVariation BEFREE In preclinical studies, afatinib not only inhibited the growth of models with common activating EGFR mutations, but was also active in lung cancer models harboring wild-type EGFR or the EGFR L858R/T790M double mutant. 23664448

2013
dbSNP: rs121434568
rs121434568
EGFR
0.100 GeneticVariation BEFREE Gefitinib greatly enhanced NK cell cytotoxicity to lung cancer cells with EGFR L858R + T790M resistance mutation. 23937717

2013
dbSNP: rs121434568
rs121434568
EGFR
0.100 GeneticVariation BEFREE In preclinical studies, afatinib not only inhibited the growth of models with common activating EGFR mutations, but was also active in lung cancer models harboring wild-type EGFR or the EGFR L858R/T790M double mutant. 23664448

2013
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.100 GeneticVariation BEFREE In EGFR mutant lung cancer, modeling of acquired resistance (AR) with drug-sensitive cell lines has identified clinically relevant EGFR tyrosine kinase inhibitor (TKI) resistance mechanisms such as the second-site mutation, EGFR T790M, amplification of the gene encoding an alternative kinase, MET, and epithelial-mesenchymal transition (EMT). 23733853

2013
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.100 GeneticVariation BEFREE In conclusion, knock-down of T790M transcript by siRNAs further decreases the cell growth of T790M mutant lung cancer cells that are treated with TKIs or cetuximab. 23266614

2013
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.100 GeneticVariation BEFREE EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung. 24029120

2013
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.100 GeneticVariation BEFREE Cell line-based assays showed that Aki1 constitutively associates with mutant EGFR in lung cancer cells with (H1975) or without (PC-9 and HCC827) T790M gatekeeper mutation. 23045273

2013
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.100 GeneticVariation BEFREE In conclusion, a low gefitinib dose caused tumors to become drug-resistant prior to acquisition of the T790M mutation or MET amplification in EGFR-mutated models of lung cancer. 24033722

2013
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.100 GeneticVariation BEFREE In preclinical studies, afatinib not only inhibited the growth of models with common activating EGFR mutations, but was also active in lung cancer models harboring wild-type EGFR or the EGFR L858R/T790M double mutant. 23664448

2013
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.100 GeneticVariation BEFREE These preclinical data suggested that downregulation of Bcl-2 by RNAi in the gefitinib-resistant H1975 lung cancer cell line with T790M mutation enhanced the effects of gefitinib and may offer a novel therapeutic strategy for the treatment of NSCLC. 23588221

2013
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.100 GeneticVariation BEFREE Clinical resistance to gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), in patients with lung cancer has been linked to acquisition of the T790M resistance mutation in activated EGFR or amplification of MET. 23592446

2013
dbSNP: rs146795390
rs146795390
EGFR
0.030 GeneticVariation BEFREE A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable? 23380224

2013
dbSNP: rs1057519847
rs1057519847
EGFR
0.100 GeneticVariation BEFREE We identified a reference range for EGFR L858R and exon 19 deletions in specimens from KRAS-mutant lung cancer, allowing identification of candidate thresholds with high sensitivity and 100% specificity. 24429876

2014
dbSNP: rs1057519847
rs1057519847
EGFR
0.100 GeneticVariation BEFREE Next, we examined the role of RhoB in lung cancer progression in transgenic mice that express inducible EGFR(L858R) crossed with Rhob null mice. 25320360

2014
dbSNP: rs1057519847
rs1057519847
EGFR
0.100 GeneticVariation BEFREE A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. 24453288

2014
dbSNP: rs1057519848
rs1057519848
EGFR
0.100 GeneticVariation BEFREE A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. 24453288

2014
dbSNP: rs1057519848
rs1057519848
EGFR
0.100 GeneticVariation BEFREE We identified a reference range for EGFR L858R and exon 19 deletions in specimens from KRAS-mutant lung cancer, allowing identification of candidate thresholds with high sensitivity and 100% specificity. 24429876

2014
dbSNP: rs1057519848
rs1057519848
EGFR
0.100 GeneticVariation BEFREE Next, we examined the role of RhoB in lung cancer progression in transgenic mice that express inducible EGFR(L858R) crossed with Rhob null mice. 25320360

2014
dbSNP: rs121434568
rs121434568
EGFR
0.100 GeneticVariation BEFREE Next, we examined the role of RhoB in lung cancer progression in transgenic mice that express inducible EGFR(L858R) crossed with Rhob null mice. 25320360

2014